Unknown

Dataset Information

0

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.


ABSTRACT:

Background

Antibody-drug conjugates have recently been introduced as a treatment for advanced urothelial carcinoma. The EV-301 study demonstrated that enfortumab vedotin (EV) improved overall survival compared with conventional chemotherapy. To assess the cost-effectiveness of EV for the treatment of advanced urothelial carcinoma (UC) from a payer perspective in middle- and high-income countries.

Methods

A decision analysis model was developed to assess the efficacy and economic viability of EV as a subsequent-line treatment following disease progression in patients with advanced urothelial carcinoma already treated with PD-1 or PD-L1 inhibitors. Clinical and utility values were obtained from the published literature and available databases. Cost data were obtained from payer perspectives in the United States, United Kingdom, and China. Quality-adjusted life-years (QALYs) were used to measure health outcomes, and incremental cost-effectiveness ratios (ICERs) used to evaluate cost-effectiveness in comparison to willingness-to-pay in the United States, United Kingdom, and China. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the model.

Results

Compared with chemotherapy, EV increased the benefit by 0.16-0.17 QALYs, resulting in ICERs of $2,168,746.71, $2,164,494.38, and $1,775,576.56 per QALY in the United States, United Kingdom, and China, respectively. One-way sensitivity analysis indicated that the largest effect on outcome was the utility value for progression-free survival. Probabilistic sensitivity analysis demonstrated that the probability of EV being cost-effective was 0%.

Conclusions

EV provides an additional health benefit over chemotherapy for patients with advanced urothelial carcinoma but is not cost-effective from a payer perspective in the United States, United Kingdom, or China.

SUBMITTER: Wu Q 

PROVIDER: S-EPMC8796084 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8450892 | biostudies-literature
| S-EPMC10476837 | biostudies-literature
| S-EPMC7780177 | biostudies-literature
| S-EPMC10852367 | biostudies-literature
| S-EPMC10486515 | biostudies-literature
| S-EPMC9939146 | biostudies-literature
| S-EPMC7340645 | biostudies-literature
| S-EPMC10362867 | biostudies-literature
| S-EPMC9762760 | biostudies-literature
| S-EPMC10262920 | biostudies-literature